FDA: No Decision On CV Outcomes Trial For Afrezza
Executive Summary
Despite the apparent lack of a cardiovascular safety signal in the inhaled insulin’s clinical program, agency says the question of whether a dedicated study would be required post-approval “is still under discussion.”